Chrome Plugin Live! Redefine the way you read FinTwit š Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
ABEO
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.23
N/A
-0.44
vsĀ -2.08
Q3.23
N/A
-0.48
vsĀ -1.48
Q4.23
N/A
-0.64
vsĀ 1.53
Q1.24
N/A
-0.53
vsĀ -0.54
Q2.24
N/A
-0.75
vsĀ -0.44
Q3.24
N/A
-0.31
vsĀ -0.48
Q4.24
N/A
-0.24
vsĀ -0.64
Q1.25
N/A
-0.24
vsĀ -0.53
Q2.25
N/A
-0.38
vsĀ -0.75
Q3.25
+146%
0.14
vsĀ -0.31
Sales Growth
YoY
Current
Estimates
Q2.23
+250%
3.5MĀ vsĀ 1M
Q3.23
NA
NAĀ vsĀ NA
Q4.23
+4053%
2.8MĀ vsĀ 68K
Q1.24
NA
NAĀ vsĀ NA
Q2.24
-100%
NAĀ vsĀ 3.5M
Q3.24
NA
NAĀ vsĀ NA
Q4.24
-100%
NAĀ vsĀ 2.8M
Q1.25
NA
NAĀ vsĀ NA
Q2.25
NA
30.4MĀ vsĀ NA
Q3.25
NA
6.6MĀ vsĀ NA
Return on Equity
QoQ
Q2.23
-178%
-1.78
vsĀ -0.49
Q3.23
-54%
-0.54
vsĀ -1.78
Q4.23
-112%
-1.12
vsĀ -0.54
Q1.24
+356%
3.56
vsĀ -1.12
Q2.24
+10%
0.1
vsĀ 3.56
Q3.24
-66%
-0.66
vsĀ 0.1
Q4.24
-21%
-0.21
vsĀ -0.66
Q1.25
-29%
-0.29
vsĀ -0.21
Institutionnal Ownership
QoQ
Q1.21
79
79
vsĀ 72
10%
Q2.21
69
69
vsĀ 79
-13%
Q3.21
56
56
vsĀ 69
-19%
Q4.21
47
47
vsĀ 56
-16%
Q1.22
49
49
vsĀ 47
4%
Q2.22
36
36
vsĀ 49
-27%
Q3.22
2
2
vsĀ 36
-94%
Q4.24
1
1
vsĀ NA
NA
Relative Strength
ABEO
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
https://www.defenseworld.net
3 hours ago
globenewswire.com
7 hours ago
globenewswire.com
7 hours ago
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
0.02Ā ( 0.34%)
After-hours 5.83$
-0.01 (-0.26%)
Relative Strenght
79
Volume Buzz
-71%
Earning Acce
No
Dist 52w H.
20%Quote Panel
Key Metrics
Forecast
NaN%2026-Revenue
158%2026-EPS
-523%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
20.00(241.88%)
Number of analyst
1
Last analyst upgrade/downgrade
Oppenheimer
initialisePrevious: Not converted
2025-03-05
Now: Outperform
H.C. Wainwright
initialisePrevious: Not converted
2024-07-03
Now: Buy
